Review Article

Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State

Masachika Senba,1 Kioko Kawai,2 and Naoki Mori3

1 Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan
2 Department of Pathology, Nagasaki Prefecture Medical Health Operation Group, Isahaya 859-0401, Japan
3 Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan

Correspondence should be addressed to Masachika Senba, mikiyo@net.nagasaki-u.ac.jp

Received 25 July 2011; Accepted 14 September 2011

Academic Editor: Kunihiro Tsukasaki

Copyright © 2012 Masachika Senba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human T-cell leukemia virus type-1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). Hypercalcemia is common in patients with ATL. These patients rarely develop metastatic calcification and acute pancreatitis. The underlying pathogenesis of this condition is osteoclast hyperactivity with associated overproduction of parathyroid hormone-related protein, which results in hypercalcemia in association with bone demineralization. The discovery of the osteoclast differentiation factor receptor activator of nuclear factor-κB ligand (RANKL), its receptor RANK, and its decoy receptor osteoprotegerin (OPG), enhanced our understanding of the mechanisms of ATL-associated hypercalcemia. Macrophage inflammatory protein-1-α, tumor necrosis factor-α, interleukin-1, and interleukin-6 are important molecules that enhance the migration and differentiation of osteoclasts and the associated enhanced production of RANKL for osteoblast formation. In this paper, we focus on metastatic calcification and acute pancreatitis in ATL, highlighting recent advances in the understanding of the molecular role of the RANKL/RANK/OPG system including its interaction with various cytokines and calciotropic hormones in the regulation of osteoclastogenesis for bone resorption in hypercalcemic ATL patients.

1. Introduction

Adult T-cell leukemia (ATL) was first reported as a new clinical entity in 1977 in Japan [1, 2]. The predominant physical findings are skin involvement, such as erythroderma and nodule formation due to the infiltration of neoplastic cells, lymphadenopathy, and hepatosplenomegaly. The ATL cells are of mature T-helper phenotype and have a characteristic appearance with especially indented or lobulated nuclei. Hypercalcemia is common in patients with ATL, and such patients often show increased numbers of osteoclasts.

A type C retrovirus was isolated from patients with cutaneous T-cell lymphoma by Poiesz and colleagues in 1980 [3]. This virus was later renamed human T-cell leukemia virus type 1 (HTLV-1). In 1981, Hinuma et al. [4] and Yoshida and colleagues [5] reported the isolation of a type C retrovirus named adult T-cell leukemia virus. The two isolates of human leukemia virus, HTLV-1, and adult T-cell leukemia virus, were later confirmed to be the same species of human retrovirus HTLV type I (US isolate) and ATLV (Japanese isolate) [6].

Approximately 16 to 20 million people are infected with HTLV-1 worldwide, and 1 to 5% of the infected individuals develop ATL during their lifetime [7] caused by the transformation of their CD4+ T cells [8]. In Japan, it is estimated that 1.2 million individuals are infected by HTLV-1, and more than 800 new cases of ATL are diagnosed each year [9]. The disease is endemic in southwest Japan, especially Okinawa, Nagasaki, Kagoshima, and Miyazaki, and also in the Caribbean islands, parts of Central Africa, South America, Melanesia, Papua New Guinea, Solomon island, and Australian aborigines [10–12].

HTLV-1 associated myelopathy was recognized in tropical areas independent of that in the Caribbean [13] and Japan [14]. Subsequently, due to its association with HTLV-1, the disease was named HTLV-1 associated myelopathy/tropical
spastic paraparesis (HAM/TSP). HAM/TSP is mainly a chronic inflammation of the white matter of the lower thoracic spinal cord, causing spastic paraparesis in the lower limbs [15]. Clinically, HAM/TSP is characterized by higher production of proinflammatory cytokines, such as interferon-γ and tumor necrosis factor-α (TNF-α), and accumulation of Tax-specific CD8+ T cells in the cerebrospinal fluid [16–20].

Patients with ATL frequently develop hypercalcemia. The authors reported four hypercalcemic ATL autopsy cases with metastatic calcifications [21, 22] including one with acute pancreatitis [21]. The reported incidence of acute pancreatitis in the registered ATL cases in Japan is 4% [23, 24]. Patients with ATL are also reported to be positive for parathyroid hormone-related protein (PTHrP) in ATL cells [25]. Furthermore, marked activation of osteoclasts was noted in the bone marrow of these patients, which could be due to the enhanced production of PTHrP in ATL cells [22].

Mechanical stresses and hormonal changes induce bone remodeling throughout the skeletal system, through osteoclastic bone resorption and osteoblastic bone formation [26]. The osteoclasts are multinucleated cells that originate from the monocytes/macrophages [27, 28]. Experimental evidence suggests that ATL cells stimulate the differentiation of hematopoietic precursors into osteoclasts [29]. The activity of osteoclasts is regulated by various cytokines and calcitropic hormones including macrophage inflammatory protein-1-alpha (MIP-1α), TNF-α, interleukin-1 (IL-1), IL-6, IL-11, macrophage-colony stimulating factors (M-CSF), PTH, PTHrP, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), and calcitonin [30–32]. Members of the TNF and TNF-receptor (TNFR) superfamily, receptor activator of nuclear factor-κB ligand (RANKL), receptor activator of nuclear factor-κB (RANK), and osteoprotegerin (OPG) also play a key role in the formation and activation of osteoclasts in conjunction with various cytokines and calcitropic hormones [30, 33, 34].

2. Metastatic Calcification

The mechanism of calcification in the viscera is categorized into two groups. Metastatic calcification with hypercalcemia occurs when calcium deposits in previously normal tissue whereas dystrophic calcification occurs in previously damaged tissue. (1) Dystrophic calcification in injured or necrotic tissue in a normal serum calcium level, such as tuberculosis, abscess, and hydatid disease. (2) Metastatic calcification can be divided into malignant and nonmalignant causes. Metastatic calcification in malignancy is reported in parathyroid carcinoma, multiple myeloma, lymphoma, leukemia, hypopharyngeal squamous cell carcinoma, synovial sarcoma, breast carcinoma, and choriocarcinoma. There are many causes of benign visceral metastatic calcification, but chronic renal failure is the most common. Most of the other benign causes are related to calcium balance, such as hypervitaminosis D and hyperparathyroidism [21, 35].

The mechanism of metastatic calcification is not clear. Metastatic calcification deposition can be influenced by release of excess calcium salts from bone, phosphate concentration, alkaline phosphatase activity, and viscera physicochemical conditions under alkalosis. The Ca₃(PO₄)₂ and CaCO₃ salts precipitate in tissues that have a favorable physicochemical environment under an alkaline pH condition. The liberated Ca₃(PO₄)₂ and CaCO₃ salts are transported via the blood in soluble form, which increased delivery and precipitation in tissues with alkalosis. Therefore, it is concluded that calcium salts precipitate in an alkaline environment [35, 36].

Hypercalcemia is one of the most difficult complication to treat in patients with ATL and a common direct cause of early death. Hypercalcemia is more severe in patients with ATL than that associated with other hematological malignancies [37]. The high frequency of hypercalcemia is the most striking feature of ATL; about 70% of ATL patients have high serum calcium levels during the clinical course of the disease, particularly during the aggressive stage of ATL [38]. Several pathological studies of ATL patients with hypercalcemia have indicated that high serum calcium levels are due to increased number of osteoclasts and accelerated bone resorption. This disease state is characterized by increased osteoclast activity with demineralization of bones and hypercalcemia. We reported previously that serum calcium levels ranged from 15.4 to 19.4 mg/dL (normal range: 8.4 to 10.4 mg/dL) in ATL patients with metastatic calcification [22]. The possibility of metastatic calcification should be considered in ATL patients associated with hypercalcemia who have abnormal shadow by roentgenogram [35, 39]. Other useful diagnostic procedures are imaging with computed tomography (CT) [35], magnetic resonance (MR) [40], and bone scintigraphy [35].

Metastatic calcification in ATL-hypercalcemia is commonly seen in alveolar septa of the lungs (Figure 1(a)), renal tubules (Figure 1(b)), and myocardium (Figure 1(c)). We reported previously the following rates of metastatic calcification in patients with ATL-hypercalcemia: tubules of kidneys: 100%, pulmonary alveolar septa of lungs: 100%, myocardium: 75%, muscular layer of stomach: 50%, lower portion of the aortic media: 50%, gastric mucosa: 25%, testicular tubules: 25%, and liver: 25% (Figure 1(d)) [22]. Metastatic calcification has also been reported in other organs, including the tongue, pancreas, and spleen [41]. Metastatic calcification of Disse’s spaces in the liver of patients with ATL was first reported by Haratake and co-workers in 1985 [42], followed by Senba and colleagues in 1990 [21].

Histopathological examination of osseous tissue sections from ATL patients with hypercalcemia show scattered osteoclasts around the cortex in the vertebrae (Figure 1(e)) [22, 36, 37, 41], although all parathyroid glands were histologically normal [22]. Osteoblast activation is accompanied by osteoclast proliferation.

3. Acute Pancreatitis with Hypercalcemia

ATL associated with hypercalcemia and acute pancreatitis was first described in 1984 by Hosokawa et al. [43], followed later by other reports in 1990s [21, 44, 45]. Hypercalcemia is difficult to treat and can be the cause of death in ATL [46, 47]. The relation between hypercalcemia and acute
pancreatitis in patients with ATL was suggested based on the observation of pancreatitis in hypercalcemic renal transplant recipients [48]. However, the exact reason linking hypercalcemia and acute pancreatitis in patients with ATL remains to be elucidated. A plausible theory [49] is the following sequence: high serum calcium levels increase calcium levels in pancreatic juice, which result in accelerated calcium-dependent conversion of trypsinogen to trypsin, leading to acute pancreatitis. Another possibility involves the high levels of nephrogenous cyclic adenosine monophosphate [47], which stimulate pancreatic secretion in the extralobular ductal system of the pancreas [50], resulting in acute pancreatitis due to occlusion of the pancreatic duct [23].

4. PTHrP and Hypercalcemia

PTHrP is a polypeptide hormone discovered in 1987 and is structurally similar to PTH [51–53]. The aminoterminal peptides of PTHrP have PTH-like actions in osseous and renal tissues by binding to a common receptor for PTH/PTHrP (PTH-1 receptor), resulting in hypercalcemia [54–56]. PTHrP was originally isolated from specific tumors as the humoral hypercalcemia of malignancy [57], and is overexpressed in many types of neoplasms [58]. Several cytokines, such as IL-1 and transforming growth factor-β (TGF-β), and PTHrP have been implicated in ATL-associated hypercalcemia. Among these factors, PTHrP is considered to
stimulate osteoclasts, resulting in increased bone resorption. Moreover, IL-2 increases PTHrP production and secretion in HTLV-1 infected T cells [59, 60]. In addition, PTHrP and IL-6 act synergistically in causing humoral hypercalcemia of malignancy [61, 62]. PTHrP is also overexpressed in ATL cells (Figure 1(f)). The HTLV-1 oncoprotein, Tax is a phosphoprotein localized in the nucleus and acts to transactivate the PTHrP gene in ATL cells and is also involved in the transcription of the PTHrP gene in vivo [63, 64]. Furthermore, Tax upregulates PTHrP gene expression in vitro and also transactivates the PTHrP promoter [65]. Other studies showed that Tax acts in synergy with Erts-1, AP-1, and AP-2, to increase PTHrP gene transcription [66, 67]. Immunodeficient mice implanted with leukemia cells from patients with ATL exhibited hypercalcemia and overexpressed PTHrP [68]. However, PTHrP cannot directly induce the differentiation of hematopoietic precursor cells to osteoclasts [69]. Furthermore, high serum levels of PTHrP are not always associated with hypercalcemia in patients with ATL, suggesting the involvement of other factors in the development of hypercalcemia [70]. The MET-1/NOD/SCID model demonstrated that RANKL expression correlates with the secretion of PTHrP and IL-6, as well as with hypercalcemia [32]. Therefore, PTHrP is not always the major mediator of hypercalcemia in humoral hypercalcemia of malignancy; rather, the latter involves many other factors.

5. Osteoclast Differentiation and Hypercalcemia

Hypercalcemia is one of the most frequent and serious complications in patients with ATL and is due to marked bone resorption associated with osteoclast accumulation. The osseous tissue is consistently remodeled by the bone forming osteoblasts and the bone resorbing osteoclasts. Osteoclasts are multinucleated giant cells present only in the bone. They are derived from hematopoietic precursor cells, and belong to the monocytes/macrophages lineage. Specifically, they are formed mononuclear preosteoclasts, which fuse to form multinucleated osteoclast. The earliest identifiable osteoclast precursor cells are the granulocyte macrophage colony forming units (CFU-GM), which give rise to granulocytes, monocytes, and osteoclasts. CFU-GM derived cells differentiate to form mononuclear preosteoclast, which fuse together to subsequently form multinucleated osteoclasts.
...factor, orange structure: OPG (osteoprotegerin), that is, osteoclastogenesis inhibitory factor. κ black structure: RANK (receptor activator of nuclear factor-

in the RANKL/RANK interaction. Blue structure: M-CSF (macrophage-colony stimulating factor), pink structure: M-CSF receptor (c-Fms). Reaction of OPG with RANKL inhibits the binding of osteoclast precursors and osteoclasts to RANKL, therefore, OPG acts as a decoy receptor osteoclasts. M-CSF is an essential factor for osteoclast proliferation and differentiation, which is produced by osteoblasts in osseous tissue. Reaction of OPG with RANKL inhibits the binding of osteoclast precursors and osteoclasts to RANKL, therefore, OPG acts as a decoy receptor in the RANKL/RANK interaction. Blue structure: M-CSF (macrophage-colony stimulating factor), pink structure: M-CSF receptor (c-Fms), black structure: RANK (receptor activator of nuclear factor-κB), red structure: RANKL (RANK ligand), that is, osteoclast differentiation factor, orange structure: OPG (osteoprotegerin), that is, osteoclastogenesis inhibitory factor. Reaction of OPG with RANKL inhibits the binding of osteoclast precursors and osteoclasts to RANKL. Therefore, OPG is produced by osteoblasts and acts as a decoy receptor by binding at high affinity to RANKL, therefore, preventing the interaction with RANK [81, 83, 84]. As a consequence of binding to RANKL, OPG acts as an effective inhibitor of osteoclast proliferation, differentiation, activation, and survival, and therefore, it inhibits bone resorption, resulting in bone protection [83]. In this regard, various metabolic regulators modulate OPG expression and secretion by osteoblasts/stromal cells. These include IL-1, TNF-α, and TGF-β, which increase OPG secretion while various stimulators of bone resorption, such as PTH, PGE2, and 1α,25(OH)2D3 reduce its secretion [78, 79, 85].

6. Molecular Mechanisms of Hypercalcemia in ATL

As discussed above, HTLV-1 is the causative factor of ATL, and patients with ATL often exhibit humoral hypercalcemia of malignancy [86], which is induced by PTHrP and cytokines, such as IL-1, IL-6, TGF-β, and MIP-1α [65, 87–94]. About 70% of ATL patients develop hypercalcemia throughout the clinical course [38]. Overexpression of the RANKL gene correlates with hypercalcemia in ATL. In vitro studies have shown that ATL cells obtained from patients with hypercalcemia, which overexpress RANKL gene transcripts, induced the differentiation of human hematopoietic precursor cells into osteoclast in the presence of M-CSF. In contrast, ATL cells from patients with normal serum calcium levels did not induce such differentiation, suggesting...
that the expression of the RANKL gene in ATL cells is involved in the induction of differentiation of these cells. These results suggest that ATL cells induce the differentiation of the hematopoietic precursor cells to osteoclast through RANKL expressed on their surface, in cooperation with M-CSF, and ultimately cause hypercalcemia [29]. In ATL patients with metastasis and hypercalcemia, activation of the MIP-1α, TNF-α, IL-1, and IL-6 molecules is induced by Tax-stimulated NF-κB activation [93, 94]. Interestingly, RANKL induces osteoclast formation through the NF-κB signaling pathway, which is critical for osteoclastogenesis. Animals lacking both the p50 and p52 subunits of NF-κB develop severe osteopetrosis [95]. These putative steps in the pathogenesis of disease are supported by evidence derived from tissue culture experiments, xenograft mouse models, and clinical observations in patients [96–100]. Moreover, amino acid sequences homologous to gp46-197 were found in the carboxyl-terminal half of OPG. Administration of the gp46-197 peptide reduced bone mineral density and in the carboxyl-terminal half of OPG. Administration of amino acid sequences homologous to gp46-197 were found to deregulate the expression of RANKL [93, 94]. Interestingly, RANKL induces osteoclast formation through the NF-κB signaling pathway, which is critical for osteoclastogenesis. Animals lacking both the p50 and p52 subunits of NF-κB develop severe osteopetrosis [95]. These putative steps in the pathogenesis of disease are supported by evidence derived from tissue culture experiments, xenograft mouse models, and clinical observations in patients [96–100]. Moreover, amino acid sequences homologous to gp46-197 were found in the carboxyl-terminal half of OPG. Administration of the gp46-197 peptide reduced bone mineral density and significantly increased serum calcium levels. The central region of HTLV-1 gp46 acts as an antagonist for OPG and promotes the development of hypercalcemia [101]. HTLV-1 infected cells were found to deregulate the expression of OPG in osteoblast precursors [102]. Ectopic expression of the HTLV-1 basic leucine zipper factor was sufficient to activate Dickkopf-1 transcription in an HTLV-1 infected and uninfected T-cell line [103]. It is possible that HTLV-1 basic leucine zipper factor activates Dickkopf-1 expression at some stage of ATL, thus, indirectly facilitating changes in RANKL and OPG expression, and contributing to the accelerated bone resorption associated with ATL [103].

Conflict of Interests

The authors declare no conflict of interests.

References

[1] K. Takatsuki, T. Uchiyama, K. Sagawa, and J. Yodoi, “Adult T-cell leukemia in Japan,” in Topics in Hematology, S. Seno, F. Takatu, and S. Irino, Eds., pp. 73–77, Excerpta Medica, Amsterdam, The Netherlands, 1977.
[2] T. Uchiyama, J. Yodoi, K. Sagawa, K. Takatsuki, and H. Uchino, “Adult T-cell leukemia: clinical and hematologic features of 16 cases,” Blood, vol. 50, no. 3, pp. 481–492, 1977.
[3] B. J. Poiesz, F. W. Russett, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo, “Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 12, pp. 7415–7419, 1980.
[4] Y. Hinuma, K. Nagata, and M. Hanaoka, “Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 10, pp. 6476–6480, 1981.
[5] M. Yoshida, I. Miyoshi, and Y. Hinuma, “Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 6, pp. 2031–2035, 1982.
[6] T. Watanabe, M. Seiki, and M. Yoshida, “HTLV type I (U.S. isolate) and ATLV (Japanese isolate) are the same species of human retrovirus,” Virology, vol. 133, no. 1, pp. 238–241, 1984.
[7] T. Ishikawa, “Current status of therapeutic approaches to adult T-Cell leukemia,” International Journal of Hematology, vol. 78, no. 4, pp. 304–311, 2003.
[8] M. Kannagi, T. Ohashi, N. Harashima, S. Hanabuchi, and A. Hasegawa, “Immunological risks of adult T-cell leukemia at primary HTLV-I infection,” Trends in Microbiology, vol. 12, no. 7, pp. 346–352, 2004.
[9] M. Matsuzoka and K. T. Jeang, “Human T-cell leukemia virus type I at age 25: a progress report,” Cancer Research, vol. 65, no. 11, pp. 4467–4470, 2005.
[10] F. A. Proietti, A. B. E. Carneiro-Proietti, B. C. Catalan-Soares, and E. L. Murphy, “Global epidemiology of HTLV-I infection and associated diseases,” Oncogene, vol. 24, no. 39, pp. 6058–6068, 2005.
[11] K. Verdonck, E. Gonzalez, S. van Dooren, A. M. Vandanme, G. Vanham, and E. Gotuzzo, “Human T-lymphotropic virus 1: recent knowledge about an ancient infection,” The Lancet Infectious Diseases, vol. 7, no. 4, pp. 266–281, 2007.
[12] D. U. Gonçalves, F. A. Proietti, J. G. R. Ribas et al., “Epidemiology, treatment, and prevention of HTLV-T-cell leukemia virus type 1-associated diseases,” Clinical Microbiology Reviews, vol. 23, no. 3, pp. 577–589, 2010.
[13] A. Gessain, F. Barin, and J. C. Vernant, “Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis,” The Lancet, vol. 2, no. 8452, pp. 407–410, 1985.
[14] M. Osame, K. Usuku, and S. Izumo, “HTLV-I associated myelopathy, a new clinical entity,” The Lancet, vol. 1, no. 8488, pp. 1031–1032, 1986.
[15] M. M. Aye, E. Matsuzaka, T. Moritoyo et al., “Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system,” Acta Neuropathologica, vol. 100, no. 3, pp. 245–252, 2000.
[16] J. A. Sakai, M. Nagai, M. B. Brennan, C. A. Mora, and S. Jacobson, “In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease: predominant expansion of CD8+ T cells,” Blood, vol. 98, no. 5, pp. 1506–1511, 2001.
[17] R. Kubota, S. S. Soldan, R. Martin, and S. Jacobson, “Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient,” Journal of NeuroVirology, vol. 8, no. 1, pp. 53–57, 2002.
[18] P. K. C. Goon, T. Igakura, E. Hanon et al., “High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secretting human T-lymphotropic virus type 1 (HTLV-I)-specific CD4+ T cells in patients with HTLV-I-associated neurological disease,” Journal of Virology, vol. 77, no. 17, pp. 9716–9722, 2003.
[19] P. A. Muraro, K. P. Wandinger, B. Bielekova et al., “Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders,” Brain, vol. 126, part 1, pp. 20–31, 2003.
[20] S. Ollindo, A. Lézin, P. Cabre et al., “HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression,” Journal of the Neurological Sciences, vol. 237, no. 1-2, pp. 53–59, 2005.
[21] M. Senba, K. Kawai, S. Chiyoda, and O. Takahara, “Metastatic liver calcification in adult T-cell leukemia-lymphoma associated with hypercalcemia,” American Journal of Gastroenterology, vol. 85, no. 9, pp. 1202–1203, 1990.
[22] M. Senba and K. Kawai, “Metastatic calcification due to hypercalcemia in adult T-cell leukemia-lymphoma (ATLL),” Zentralblatt für Pathologie, vol. 137, no. 4, pp. 341–345, 1991.

[23] M. Senba, T. Nakamura, K. Kawai, and M. I. Senba, “HTLV-I and acute pancreatitis,” The Lancet, vol. 337, no. 8755, p. 1489, 1991.

[24] M. Senba and M. I. Senba, “Acute pancreatitis associated with hypercalcemia in adult T-cell leukemia-lymphoma,” Journal of Gastroenterology and Hepatology, vol. 11, no. 2, pp. 180–182, 1996.

[25] M. Senba and K. Kawai, “Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukemia-lymphoma,” European Journal of Haematology, vol. 48, no. 5, pp. 278–279, 1992.

[26] S. C. Manolagas, “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” Endocrine Reviews, vol. 21, no. 2, pp. 115–137, 2000.

[27] M. Koide, S. Kinugawa, N. Takahashi, and N. Udagawa, “Osteoclastic bone resorption induced by innate immune responses,” Periodontology 2000, vol. 54, no. 1, pp. 235–246, 2010.

[28] H. Takayanagi, “New immune connections in osteoclast formation,” Annals of the New York Academy of Sciences, vol. 1192, pp. 117–123, 2010.

[29] K. Nosaka, T. Miyamoto, T. Sakai, H. Mitsuya, T. Suda, and M. Matsuoka, “Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor-κB ligand on adult T-cell leukemia cells,” Blood, vol. 99, no. 2, pp. 634–640, 2002.

[30] G. D. Roodman, “Regulation of osteoclast differentiation,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 100–109, 2006.

[31] D. Vega, N. M. Maalouf, and K. Sakhaee, “Clinical review: the role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implications,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4514–4521, 2007.

[32] C. Parrula, B. Zimmerman, P. Nadella et al., “Expression of tumor invasion factors determines systemic engraftment and induction of humoral hypercalcemia in a mouse model of adult T-cell leukemia,” Veterinary Pathology, vol. 46, no. 5, pp. 1003–1014, 2009.

[33] S. Fili, M. Karalaki, and B. Schaller, “Therapeutic implications of osteoprotegerin,” Cancer Cell International, vol. 9, p. 26, 2009.

[34] A. P. Trouvin and V. Goeb, “Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss,” Clinical Interventions in Aging, vol. 5, pp. 345–354, 2010.

[35] E. D. Chan, D. V. Morales, C. H. Welsh, M. T. McDermott, and M. I. Schwarz, “Calcium deposition with or without bone formation in the lung,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 12, pp. 1654–1669, 2002.

[36] R. M. Mulligan, “Metastatic calcification,” Archives of Pathology, vol. 43, no. 2, pp. 177–230, 1947.

[37] G. D. Roodman, “Mechanisms of bone lesions in multiple myeloma and lymphoma,” Cancer, vol. 80, no. 8, pp. 1557–1563, 1997.

[38] T. Kiyokawa, K. Yamaguchi, and M. Takeya, “Hypercalcemia and osteoclast proliferation in adult T-cell leukemia,” Cancer, vol. 59, no. 6, pp. 1187–1191, 1987.

[39] M. Nakamura, A. Ohishi, R. Watanabe et al., “Adult T-cell leukemia with hypercalcemia-induced metastatic calcification in the lungs due to production of parathyroid hormone-related protein,” Internal Medicine, vol. 40, no. 5, pp. 409–413, 2001.

[40] Y. Taguchi, G. Fuyuno, S. Shiroya et al., “MR appearance of pulmonary metastatic calcification,” Journal of Computer Assisted Tomography, vol. 20, no. 1, pp. 38–41, 1996.

[41] H. Kumamoto, R. Ichinohasama, T. Sawai et al., “Multiple organ failure associated with extensive metastatic calcification in a patient with an intermediate state of human T lymphotrophic virus type I (HTLV-I) infection: report of an autopsy case,” Pathology International, vol. 48, no. 4, pp. 313–318, 1998.

[42] J. Haratake, N. Ishii, A. Horie, M. Matsumoto, S. Oda, and K. Satoh, “Adult T-cell leukemia complicated by hypercalcemia: report of three autopsy cases with special reference to the etiologic factor of hypercalcemia,” Acta Pathologica Japonica, vol. 35, no. 2, pp. 437–448, 1985.

[43] T. Hosokawa, T. Itoya, Y. Saburi, R. Mizutani, T. Fujioka, and H. Yamashita, “An autopsy case of adult T cell leukemia died of acute hemorrhagic pancreatitis,” Journal of Kyushu Hematological Society, vol. 32, no. 3–4, pp. 75–81, 1984, (in Japanese with English abstract).

[44] Y. Dazai, I. Kato, Y. Hara, R. Yoshida, and K. Kurihara, “Two cases of adult T-cell leukemia associated with acute pancreatitis due to hypercalcemia,” American Journal of Medicine, vol. 90, no. 2, pp. 231–234, 1991.

[45] Y. Ono, T. Kimura, I. Nakano et al., “Acute pancreatitis induced by hypercalcemia associated with adult T-cell leukemia: a case report,” Journal of Gastroenterology and Hepatology, vol. 11, no. 2, pp. 193–195, 1996.

[46] K. Kinoshita, S. Kamihira, and S. Ikeda, “Clinical, hematologic, and pathologic feature of leukemic T-cell lymphoma,” Cancer, vol. 50, no. 8, pp. 1554–1562, 1982.

[47] S. Fukumoto, T. Matsumoto, K. Ikeda et al., “Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma,” Archives of Internal Medicine, vol. 148, no. 4, pp. 921–925, 1988.

[48] T. W. Frick, D. S. Fryd, D. E. R. Sutherland, R. L. Simmons, and J. S. Najarian, “Hypercalcemia associated with pancreatitis and hyperamylasemia in renal transplant recipients. Data from the Minnesota randomized trial of cyclosporine versus antilymphoblast azathioprine,” American Journal of Surgery, vol. 154, no. 5, pp. 487–489, 1987.

[49] T. R. Kelly, “Relationship of hyperparathyroidism to pancreatitis,” Archives of Surgery, vol. 97, no. 2, pp. 267–274, 1968.

[50] F. B. Thomas, D. Sinar, J. H. Caldwell, H. S. Mekhjian, and J. M. Falko, “Stimulation of pancreatic secretion of water and electrolytes by furosemide,” Gastroenterology, vol. 73, no. 2, pp. 221–225, 1977.

[51] L. J. Suva, G. A. Winslow, and R. E. H. Wettenhall, “A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression,” Science, vol. 237, no. 4817, pp. 893–896, 1987.

[52] G. J. Strewler, P. H. Stern, J. W. Jacobs et al., “Parathyroid hormone-like protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone,” Journal of Clinical Investigation, vol. 80, no. 6, pp. 1803–1807, 1987.

[53] W. J. Burris, T. Wu, and C. Bunch, “Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with...
humoral hypercalcemia of malignancy,” *Journal of Biological Chemistry*, vol. 262, no. 15, pp. 7151–7156, 1987.

[54] N. Horiiuchi, M. P. Caulfield, J. E. Fisher et al., “Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro,” *Science*, vol. 238, no. 4833, pp. 1566–1568, 1987.

[55] B. E. Kemp, J. M. Moseley, C. P. Rodda et al., “Parathyroid hormone related protein of malignancy: active synthetic fragments,” *Science*, vol. 238, no. 4833, pp. 1568–1570, 1987.

[56] T. Watanabe, K. Yamaguchi, K. Takatsuki, M. Osame, and M. Ota, “Interleukin-2 increases production and secretion of parathyroid hormone-related protein by human T-cell leukemia virus type I-infected T cells: possible role in hypercalcemia associated with adult T cell leukemia,” *Endocrinology*, vol. 132, no. 6, pp. 2551–2556, 1993.

[57] N. Mori, K. Ohsumi, S. Murakami et al., “Enhancing effect of interleukin-2 on production of parathyroid hormone-related protein by adult T-Cell leukemia cells,” *Japanese Journal of Cancer Research*, vol. 84, no. 4, pp. 425–430, 1993.

[58] M. Ohmori, M. Nagai, M. Fujita et al., “A novel mature B-cell line (DOBIL-6) producing both parathyroid hormone-related protein and interleukin-6 from a myeloma patient presenting with hypercalcemia,” *British Journal of Haematology*, vol. 101, no. 4, pp. 688–693, 1998.

[59] N. Ota, T. Nakajima, I. Nakazawa et al., “A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density,” *Journal of Human Genetics*, vol. 46, no. 5, pp. 267–272, 2001.

[60] G. Franchini, F. Wong-Staal, and R. C. Gallo, “Human T-cell leukemia virus (HTLV-1) transcripts in fresh and cultured cells of patients with adult T-cell leukemia,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 81, no. 19, pp. 6207–6211, 1984.

[61] T. Watanabe, K. Yamaguchi, K. Takatsuki, M. Osame, and M. Yoshida, “ Constitutive expression of parathyroid hormone-related protein gene in human T-cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients and viral carriers by using the polymerase chain reaction,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 86, no. 14, pp. 5620–5624, 1989.

[62] T. Prager, J. D. Rosenblatt, and E. Eijima, “Hypercalcemia, parathyroid hormone-related protein expression and human T-cell leukemia virus infection,” *Leukemia and Lymphoma*, vol. 14, no. 5–6, pp. 395–400, 1994.

[63] A. Takaori-Kondo, K. Imada, I. Yamamoto et al., “Parathyroid hormone-related protein-induced hypercalcemia in SCID mice engrafted with adult T-cell leukemia cells,” *Blood*, vol. 91, no. 12, pp. 4747–4751, 1998.

[64] K. Matsuizaki, K. Katayama, Y. Takahashi et al., “Parosteal-like cells are formed from peripheral blood mononuclear cells in coculture with SaOS-2 cells transfected with the parathyroid hormone (PTH1)/PTH-related protein receptor gene,” *Endocrinology*, vol. 140, no. 2, pp. 925–932, 1999.

[65] T. J. Rosol and C. C. Capen, “Pathogenesis of humoral hypercalcemia of malignancy,” *Domestic Animal Endocrinology*, vol. 5, no. 1, pp. 1–21, 1988.

[66] A. E. Broadus, M. Mangin, K. Ikeda et al., “Humoral hypercalcemia of cancer: identification of a novel parathyroid hormone-like peptide,” *The New England Journal of Medicine*, vol. 319, no. 9, pp. 556–563, 1988.

[67] K. Ikeda, R. Okazaki, D. Inoue, H. Ohno, E. Ogata, and T. Matsumoto, “Interleukin-2 increases production and secretion of parathyroid hormone-related peptide by human T-cell leukemia virus type I-infected T cells; possible role in hypercalcemia associated with adult T cell leukemia,” *Endocrinology*, vol. 112, no. 6, pp. 2551–2556, 1993.

[68] N. Mori, K. Ohsumi, S. Murakami et al., “Enhancing effect of interleukin-2 on production of parathyroid hormone-related protein by adult T-Cell leukemia cells,” *Japanese Journal of Cancer Research*, vol. 84, no. 4, pp. 425–430, 1993.

[69] M. Ohmori, M. Nagai, M. Fujita et al., “A novel mature B-cell line (DOBIL-6) producing both parathyroid hormone-related protein and interleukin-6 from a myeloma patient presenting with hypercalcemia,” *British Journal of Haematology*, vol. 101, no. 4, pp. 688–693, 1998.

[70] H. L. Wright, H. S. McCarthy, J. Middleton, and M. J. Marshall, “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,” *Cell*, vol. 93, no. 2, pp. 165–176, 1998.

[71] M. A. T. Suda and N. Takahashi, “Contributions to osteoclast biology from Japan,” *Proceedings of the Japan Academy Series B*, vol. 84, no. 10, pp. 419–438, 2008.

[72] J. M. Blair, Y. Zheng, and C. R. Dunstan, “RANK ligand,” *International Journal of Biochemistry and Cell Biology*, vol. 39, no. 6, pp. 1077–1081, 2007.

[73] H. Hsu, D. L. Lacey, C. R. Dunstan et al., “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 7, pp. 3540–3545, 1999.

[74] D. M. Anderson, E. Maraskovsky, W. L. Billingsley et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,” *Nature*, vol. 390, no. 6656, pp. 175–179, 1997.

[75] L. C. Hofbauer and M. Schoppert, “Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases,” *Journal of the American Medical Association*, vol. 292, no. 4, pp. 490–495, 2004.

[76] H. L. Wright, H. S. McCarthy, J. Middleton, and M. J. Marshall, “RANK, RANKL and osteoprotegerin in bone biology and disease,” *Current Reviews in Musculoskeletal Medicine*, vol. 2, no. 1, pp. 56–64, 2009.

[77] E. A. O’Brien, J. H. H. Williams, and M. J. Marshall, “Osteoprotegerin is present on the membrane of osteoclast-like cells and its presence is related to the formation of osteoclast-like cells,” *Bone*, vol. 28, no. 2, pp. 208–214, 2001.

[78] W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,” *Cell*, vol. 93, no. 2, pp. 165–176, 1998.

[79] M. A. T. Suda and N. Takahashi, “Contributions to osteoclast biology from Japan,” *Proceedings of the Japan Academy Series B*, vol. 84, no. 10, pp. 419–438, 2008.

[80] J. M. Blair, Y. Zheng, and C. R. Dunstan, “RANK ligand,” *International Journal of Biochemistry and Cell Biology*, vol. 39, no. 6, pp. 1077–1081, 2007.

[81] H. Hsu, D. L. Lacey, C. R. Dunstan et al., “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 7, pp. 3540–3545, 1999.

[82] D. M. Anderson, E. Maraskovsky, W. L. Billingsley et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,” *Nature*, vol. 390, no. 6656, pp. 175–179, 1997.

[83] L. C. Hofbauer and M. Schoppert, “Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases,” *Journal of the American Medical Association*, vol. 292, no. 4, pp. 490–495, 2004.

[84] H. L. Wright, H. S. McCarthy, J. Middleton, and M. J. Marshall, “RANK, RANKL and osteoprotegerin in bone biology and disease,” *Current Reviews in Musculoskeletal Medicine*, vol. 2, no. 1, pp. 56–64, 2009.
[83] Y. Y. Kong, W. J. Boyle, and J. M. Penninger, “Osteoprotegerin ligand: a regulator of immune responses and bone physiology,” *Immunology Today*, vol. 21, no. 10, pp. 495–502, 2000.

[84] B. Bolon, C. Carter, M. Daris et al., “Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis,” *Molecular Therapy*, vol. 3, no. 2, pp. 197–205, 2001.

[85] T. Kondo, R. Kitazawa, S. Maeda, and S. Kitazawa, “1α,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways,” *Journal of Bone and Mineral Research*, vol. 19, no. 9, pp. 1411–1419, 2004.

[86] T. Watanabe, “HTLV-V-1-associated diseases,” *International Journal of Hematology*, vol. 66, no. 3, pp. 257–278, 1997.

[87] Y. Wano, T. Hattori, M. Matsuoka et al., “Interleukin 1 gene expression in adult T cell leukemia,” *Journal of Clinical Investigation*, vol. 80, no. 3, pp. 911–916, 1987.

[88] Y. Niitsu, Y. Urushizaki, Y. Koshida et al., “Expression of TGF-beta gene in adult T cell leukemia,” *Blood*, vol. 71, no. 1, pp. 263–266, 1988.

[89] S. Honda, K. Yamaguchi, Y. Miyake et al., “Production of parathyroid hormone-related protein in adult T-cell leukemia cells,” *Japanese Journal of Cancer Research*, vol. 79, no. 12, pp. 1264–1268, 1988.

[90] S. J. Kim, J. H. Kehrl, J. Burton et al., “Transactivation of the transforming growth factor β1 (TGF-β1) gene by human T lymphotrophic virus type I Tax: a potential mechanism for the increased production of TGF-β1 in adult T cell leukemia,” *Journal of Experimental Medicine*, vol. 172, no. 1, pp. 121–129, 1990.

[91] P. M. Villiger, M. T. Cronin, T. Amenomori, W. Wachsman, and M. Lotz, “IL-6 production by human T lymphocytes. Expression in HTLV-I-infected but not in normal T cells,” *Journal of Immunology*, vol. 146, no. 2, pp. 550–559, 1991.

[92] Y. Okada, J. Tsukada, K. Nakano, S. Tonai, S. Mine, and Y. Tanaka, “Macrophage inflammatory protein-1α induces hypercalcemia in adult T-cell leukemia,” *Journal of Bone and Mineral Research*, vol. 19, no. 7, pp. 1105–1111, 2004.

[93] M. Matsuoka, “Human T-cell leukemia virus type I and adult T-cell leukemia,” *Oncogene*, vol. 22, no. 33, pp. 5131–5140, 2003.

[94] M. Matsuoka and K. T. Jeang, “Human T-cell leukemia virus type 1 (HTLV-I) infectivity and cellular transformation,” *Nature Reviews Cancer*, vol. 7, no. 4, pp. 270–280, 2007.

[95] X. Lianping, T. P. Bushnell, C. Louise et al., “NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis,” *Journal of Bone and Mineral Research*, vol. 17, no. 7, pp. 1200–1210, 2002.

[96] M. D. Lairmore, L. Silverman, and L. Ratner, “Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation,” *Oncogene*, vol. 24, no. 39, pp. 6005–6015, 2005.

[97] M. Z. Dewan, K. Terasima, M. Taruiishi et al., “Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/γcnull mice: suppression by an inhibitor against NF-κB,” *Journal of Virology*, vol. 77, no. 9, pp. 5286–5294, 2003.

[98] Y. Liu, K. Dole, J. R. L. Stanley et al., “Engraftment and tumorigenesis of HTLV-I transformed T cell lines in SCID/bg and NOD/SCID mice,” *Leukemia Research*, vol. 26, no. 6, pp. 561–567, 2002.

[99] T. Ohnuki, K. Yamaguchi, T. Kumasaka et al., “Rapid tumor death model for evaluation of new therapeutic agents for adult T-cell leukemia,” *Laboratory Investigation*, vol. 84, no. 2, pp. 263–266, 2004.

[100] V. Richard, M. D. Lairmore, P. L. Green et al., “Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotrophic virus type-1 tax expression,” *American Journal of Pathology*, vol. 158, no. 6, pp. 2219–2228, 2001.

[101] Y. Sagara, Y. Inoue, Y. Sagara, and S. Kashiwagi, “Involvement of molecular mimicry between human T-cell leukemia virus type 1 gp46 and osteoprotegerin in induction of hypercalcemia,” *Cancer Science*, vol. 100, no. 3, pp. 490–496, 2009.

[102] S. T. Shu, C. K. Martin, N. K. Thudi, W. P. Dirksen, and T. J. Rosol, “Osteolytic bone resorption in adult T-cell leukemia/lymphoma,” *Leukemia and Lymphoma*, vol. 51, no. 4, pp. 702–714, 2010.

[103] N. Polakowski, H. Gregory, J. M. Mesnard, and I. Lemasson, “Expression of a protein involved in bone resorption, Dkk1, is activated by HTLV-I bZIP factor through its activation domain,” *Retrovirology*, vol. 7, p. 61, 2010.
Submit your manuscripts at
http://www.hindawi.com